Becton, Dickinson and Company (NYSE:BDX) Announces Quarterly Earnings Results

Becton, Dickinson and Company (NYSE:BDX) posted its earnings results on Thursday. The medical instruments supplier reported $3.17 earnings per share for the quarter, topping analysts’ consensus estimates of $2.97 by $0.20, RTT News reports. The firm had revenue of $5.05 billion for the quarter, compared to the consensus estimate of $5.04 billion. Becton, Dickinson and Company had a return on equity of 13.90% and a net margin of 6.76%. The business’s revenue for the quarter was up 4.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.86 EPS. Becton, Dickinson and Company updated its FY24 guidance to $12.95-13.15 EPS.

Becton, Dickinson and Company Stock Performance

NYSE:BDX traded down $5.67 during trading hours on Friday, reaching $234.68. The company had a trading volume of 1,722,353 shares, compared to its average volume of 1,291,373. The firm’s 50 day moving average price is $238.68 and its 200-day moving average price is $240.71. The firm has a market cap of $67.80 billion, a price-to-earnings ratio of 51.68, a PEG ratio of 1.98 and a beta of 0.45. The company has a current ratio of 1.41, a quick ratio of 0.64 and a debt-to-equity ratio of 0.62. Becton, Dickinson and Company has a 52 week low of $229.40 and a 52 week high of $287.32.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be paid a $0.95 dividend. This represents a $3.80 annualized dividend and a dividend yield of 1.62%. The ex-dividend date is Monday, June 10th. Becton, Dickinson and Company’s dividend payout ratio is currently 83.70%.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, SVP Thomas J. Spoerel sold 282 shares of Becton, Dickinson and Company stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the transaction, the senior vice president now directly owns 2,276 shares in the company, valued at $542,348.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Thomas J. Spoerel sold 282 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $238.29, for a total value of $67,197.78. Following the transaction, the senior vice president now owns 2,276 shares of the company’s stock, valued at $542,348.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Michael David Garrison sold 1,715 shares of the business’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total value of $399,269.15. Following the transaction, the executive vice president now owns 5,381 shares of the company’s stock, valued at $1,252,750.61. The disclosure for this sale can be found here. 0.31% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, Barclays increased their price objective on Becton, Dickinson and Company from $301.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Moderate Buy” and an average target price of $280.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.